Why Study Neuroinflammation?
Why are we spending millions of dollars going after the same targets that aren’t working? Current drug development in this area focuses heavily on the symptoms of neuroinflammation and neurodegeneration and on replenishing degenerating neurons, when a holistic approach – evaluating the whole patient – might find more success. Of course, drug discovery for neuroinflammatory conditions faces unique challenges. Not only must our therapies cross the blood-brain barrier, but we must identify biomarkers to halt the progression of disease.
Researchers have recently identified alternative pathways whereby the immune privilege of the brain is no longer absolute. One such method looks at how the gut microbiome may influence and perhaps precede neuroinflammatory and neurodegenerative events. These events can be years in the making, prior to any sign or symptom of neurological disease.
Watch our Neuroinflammation Symposium Video Series to learn how some of the world’s leading scientists are overcoming these challenges and re-shaping how we think about treating neuroinflammation and neurodegeneration.
Neuroinflammation Symposium Proceeds Donated to Charity
As part of our patient advocacy program, Charles River donated all Neuroinflammation Symposium registration fees to the Multiple System Atrophy Coalition. Watch the videos to learn about this rare neurodegenerative movement disorder and other devastating neuroinflammatory disorders. For a complete synopsis of the event, read our eureka blog post.
Neuroinflammation Symposium Video Highlights
Opening Remarks: Charles River donates to the Multiple System Atrophy Coalition | Carina Peritore
Keynote speaker: The Gut-Brain Axis in Parkinson’s Disease | Malu Tansey
Multiple System Atrophy: A Devastating Glio-neuronal Synucleinopathy | Vikram Khurana
Panel Discussion: The Role of Gut Microbiome in Brain Function | Steve Festin, Irah King, Danielle Counotte, Malu Tansey, Kim Tang, and Rana Samadfam
LPS-Induced Neuroinflammation: In Vitro and In Vivo Assays for Development of New Treatment Strategies | Diana Misczcuk